Stockscreener 앱 받기
48.66
1.28%
-0.63
시간 외 거래:
48.85
0.19
+0.39%
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Cytokinetics, Incorporated $CYTK Shares Acquired by Mirador Capital Partners LP - MarketBeat
Aug Breakouts: Is Cytokinetics Incorporated trading at a discount2025 Earnings Impact & Risk Adjusted Buy and Sell Alerts - khodrobank.com
Moving Averages: Is Blue Owl Capital Inc.’s ROE strong enough2025 Breakouts & Breakdowns & Verified Short-Term Plans - khodrobank.com
Cytokinetics (NASDAQ:CYTK) CEO Sells $248,850.00 in Stock - MarketBeat
E. Ohman J or Asset Management AB Buys 77,806 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Intech Investment Management LLC Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17 - Bluefield Daily Telegraph
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights – CYTK - GlobeNewswire Inc.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action - Business Wire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - Morningstar
CYTK STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Cytokinetics, Incorporated Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 17, 2025 to Discuss Your RightsCYTK - PR Newswire
CYTK LAWSUIT ALERT: Levi & Korsinsky Notifies Cytokinetics, Incorporated InvestorsLead Plaintiff Deadline November 17, 2025 - ACCESS Newswire
Cytokinetics Investor Sues Over Heart Drug Approval Claims - Law360
Cytokinetics, Inc. Investigated by the Portnoy Lawfirm - GlobeNewswire
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
What are the future prospects of Cytokinetics IncorporatedTrade Entry Report & AI Enhanced Execution Alerts - khodrobank.com
CYTOKINETICS ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
Law Offices of Howard G. Smith Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire About Securities Fraud Class Action - MarketScreener
United Services Automobile Association Invests $331,000 in Cytokinetics, Incorporated $CYTK - MarketBeat
Investors Urged to Contact Levi & Korsinsky for Information Before November 17, 2025Cytokinetics, Incorporated (CYTK) - Newsfile
Cytokinetics, Incorporated (CYTK) LawsuitInvestors Urged to Contact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
Cytokinetics announces inducement grants - MarketScreener
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Is Cytokinetics Incorporated affected by consumer sentimentMarket Trend Report & Fast Entry and Exit Trade Plans - khodrobank.com
Cytokinetics Investor Sues Over Heart Drug’s FDA Approval Delay - Bloomberg Law News
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - Bluefield Daily Telegraph
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has B - GuruFocus
Growth Value: Will Cytokinetics Incorporated outperform its industry peersQuarterly Portfolio Report & AI Based Trade Execution Alerts - khodrobank.com
Cytokinetics (CYTK) Drops on $650-Million Debt Issuance - Yahoo Finance
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Shareholders Filed a Lawsuit Against Cytokinetics for Misleading FDA Timeline - TradingView
Cytokinetics ($CYTK) Delayed Drug Review Due to Incomplete FDA Submission Case - TradingView
Cytokinetics to Present Key Findings on Aficamten at HFSA Annual Scientific Meeting 2025 - Quiver Quantitative
Cytokinetics announces three upcoming presentations at the HFSA Annual Scientific Meeting 2025 - MarketScreener
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025 - Yahoo Finance
Levi & Korsinsky Notifies Cytokinetics, Incorporated (CYTK) Shareholders of Class Action Lawsuit and November 17, 2025 Deadline - ACCESS Newswire
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment stock outlook - Investing.com
Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit - PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Cytokinetics, Incorporated Common Stock and Sets a Lead Plaintiff Deadline of November 17, 2025 - GlobeNewswire
X4 Pharmaceuticals restructures; Cytokinetics targets $650M raise - Endpoints News
Cytokinetics (CYTK) Rises on Convertible Note Offering Plan - GuruFocus
Cytokinetics rises after upsized $650 mln convertible bonds sale - TradingView
Woodline Partners LP Grows Stock Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Prices Upsized $650 Million Private Convertible Notes Offering - MarketScreener
Cytokinetics Upsizes Convertible Notes Offering To $650 Mln - Nasdaq
Cytokinetics (CYTK) Boosts Convertible Note Offering to $650M - GuruFocus
Cytokinetics prices $650 million convertible notes offering By Investing.com - Investing.com Canada
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes - The Manila Times
Cytokinetics Inc prices its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 - MarketScreener
$650 Million Debt Refinancing: Cytokinetics Slashes Interest Rate to 1.75% in Strategic Note Offering - Stock Titan
Cytokinetics Inc Prices Its Offering Of $650.0 Million Aggregate Principal Amount Of 1.75% Convertible Senior Notes Due 2031 - TradingView
Cytokinetics, Incorporated $CYTK Stake Boosted by Bayforest Capital Ltd - MarketBeat
Pullback Watch: What are the future prospects of Cytokinetics IncorporatedShare Buyback & Low Drawdown Investment Strategies - خودرو بانک
Cytokinetics, Incorporated announced that it expects to receive $550 million in funding - MarketScreener
Cytokinetics plans $550 million convertible notes offering By Investing.com - Investing.com Canada
Resistance Check: Will Recon Technology Ltd outperform small cap indexes2025 Valuation Update & Safe Entry Zone Tips - khodrobank.com
Cytokinetics, Inc. Experiences Evaluation Revision Amidst Mixed Market Signals - Markets Mojo
Cytokinetics participates in FDA late cycle meeting for NDA for aficamtenSEC filing - MarketScreener
Cytokinetics Plans $550 Million Convertible Notes Offering - MarketScreener
1.43%
0.09%
자본화:
|
볼륨(24시간):